# AK112 in Advanced Non-Small Cell Lung Cancer

> **NCT05499390** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Akeso** · enrollment: 398 (actual)

## Conditions studied

- Advanced Non-small-cell Lung Cancer

## Interventions

- **DRUG:** AK112
- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT05499390
- **Lead sponsor:** Akeso
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-11-09
- **Primary completion:** 2024-01-29
- **Final completion:** 2026-12-31
- **Target enrollment:** 398 (ACTUAL)
- **Last updated:** 2026-03-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05499390

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05499390, "AK112 in Advanced Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT05499390. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*